Optimization of Hepatic Hemodynamics During Liver Surgery

Effects of Vasopressin and Nitroglycerine in Combination on Splanchnic Blood Flow, and on Hepatic and Portal Venous Pressures in Liver Resection

Status

Completed

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02993640

Enrollment

Registered

2016-12-15

Start date

2016-09-30

Completion date

2017-03-20

Last updated

2018-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic Hemodynamics, Liver Surgery, Portal Blood Pressure

Keywords

vasopressin, nitroglycerine, portal pressure, portal flow

Brief summary

The purpose of this study is to determine if vasopressin and nitroglycerin in combination will affect hepatic hemodynamics, in the setting of liver surgery.

Detailed description

The patients in this study (undergoing elective liver resection) will be anesthetized according to routine practice in our hospital. A radial arterial catheter and a central venous catheter will be inserted, as well as a femoral arterial catheter for Picco monitoring. After the dissection phase, catheters will be inserted in the portal and hepatic veins by the surgeon. Base line data (HR, CVP, MAP, CO from thermodilution, portal and hepatic venous pressure, blood gases from radial artery, vena cava superior, hepatic vein and portal vein) will be obtained twice, with 10 minutes of steady state in between. An infusion of vasopressin 4,8 U/h will then be started and continued for 20 minutes. Data will be collected again, and an infusion of nitroglycerine (to a target of MAP 60 mmHg) will be added. After 5 minutes of steady MAP 55-65, the last set of data is collected. 12 Patients will be recruited, and the total data collection is estimated to be completed and assessed after six to nine months.

Interventions

DRUGvasopressin + nitro

vasopressin infusion 4,8 U/h for 20 minutes, thereafter nitroglycerine infusion to a MAP of 60 for 5 minutes.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients within ASA-class I-II scheduled for open liver resection

Exclusion criteria

* ASA-class III and IV, more than 2 medications for hypertension, BMI \> 35, technical difficulties with insertion av catheters, extensive surgery.

Design outcomes

Primary

Measure	Time frame
Portal and hepatic venous flow after vasopressin and nitroglycerine infusion	six - nine months
Pressure in the hepatic and portal veins after vasopressin and nitrovasopressin infusion	six - nine months

Secondary

Measure	Time frame
lactate in the splanchnic circulation	six-nine months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026